A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

RSV is the leading cause of hospitalization in infants up to 1 year old. Most babies with RSV need extra oxygen; doctors help support their breathing for two or three days, and then they get better.

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. Paris, June 9, 2025. Sanofi is shipping Beyfortus starting in early Q3 to ...

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can help prevent this potentially severe illness. CNN’s Meg Tirrell tours ...

Sanofi noted that Beyfortus will be provided in hospital prior to discharge for babies born during RSV season and is available through primary care providers or public health in Quebec, Ontario ...

Infant RSV hospitalisations fell 69 per cent in Spain during the 2024 to 2025 season compared with the 2022 to 2023 season, when immunisation therapies were unavailable. Rates decreased almost 27 ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Weekly hospital admission rates for RSV have doubled over the past month among children. In the week ending November 18, there were about 23 hospitalizations for every 100,000 children under 5.

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November ...